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Abstract
Background: The wide range of fresh gas flow - vaporizer setting (FGF - FD) combinations used by different
anesthesiologists during the wash-in period of inhaled anesthetics indicates that the selection of FGF and FD is
based on habit and personal experience. An empirical model could rationalize FGF - FD selection during wash-in.
Methods: During model derivation, 50 ASA PS I-II patients received desflurane in O2 with an ADU
® anesthesia
machine with a random combination of a fixed FGF - FD setting. The resulting course of the end-expired
desflurane concentration (FA) was modeled with Excel Solver, with patient age, height, and weight as covariates;
NONMEM was used to check for parsimony. The resulting equation was solved for FD, and prospectively tested by
having the formula calculate FD to be used by the anesthesiologist after randomly selecting a FGF, a target FA (FAt),
and a specified time interval (1 - 5 min) after turning on the vaporizer after which FAt had to be reached. The
following targets were tested: desflurane FAt 3.5% after 3.5 min (n = 40), 5% after 5 min (n = 37), and 6% after 4.5
min (n = 37).
Results: Solving the equation derived during model development for FD yields FD=-(e
(-FGF*-0.23+FGF*0.24)*(e(FGF*-0.23)
*FAt*Ht*0.1-e
(FGF*-0.23)*FGF*2.55+40.46-e(FGF*-0.23)*40.46+e(FGF*-0.23+Time/-4.08)*40.46-e(Time/-4.08)*40.46))/((-1+e(FGF*0.24))*(-1
+e(Time/-4.08))*39.29). Only height (Ht) could be withheld as a significant covariate. Median performance error and
median absolute performance error were -2.9 and 7.0% in the 3.5% after 3.5 min group, -3.4 and 11.4% in the 5%
after 5 min group, and -16.2 and 16.2% in the 6% after 4.5 min groups, respectively.
Conclusions: An empirical model can be used to predict the FGF - FD combinations that attain a target end-
expired anesthetic agent concentration with clinically acceptable accuracy within the first 5 min of the start of
administration. The sequences are easily calculated in an Excel file and simple to use (one fixed FGF - FD setting),
and will minimize agent consumption and reduce pollution by allowing to determine the lowest possible FGF that
can be used. Different anesthesia machines will likely have different equations for different agents.
Background
What fresh gas flow - vaporizer setting (FGF - FD) combi-
nation should be used for a particular patient when start-
ing the administration of potent inhaled anesthetics to
reach a target end-expired concentration (FA) after a pre-
determined time interval without excessively wasting
potent inhaled anesthetic? The wide range of FGF - FD
combinations used by different anesthesiologists during
the wash-in period of potent inhaled anesthetics indicates
that the selection of FGF and FD is based on habit and
personal experience. Some anesthesiologists use a high
FGF (to shorten the wash-in time constant of the anesthe-
sia circle breathing system, and to avoid rebreathing that
results in dilution of FD), while others prefer to use a
lower FGF in combination with a higher FD (to compen-
sate for the longer wash-in time constant, and to reduce
agent consumption). While all anesthesiologists swiftly
attain the target FA (FAt) because FGF and FD can be
adjusted according to the measured FA, it is unlikely that
the particular FGF - FD combination used was that with
the least number of FD and FGF adjustments and mini-
mum waste. The use of high FGF, even for a seemingly
brief period (5 min), may increase agent consumption
above that of an ensuing one hour maintenance phase
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with a 1 L. min-1 FGF [1], and may forfeit the savings of an
automated closed-circuit anesthesia machine [2].
Instead of relying on personal preference, we hypothe-
size that very specific FGF - FD combinations can be
used in the individual patient to attain a FAt within a
specified time interval by using an empirical model of
the kinetics of inhaled anesthetics during wash-in. Sim-
ple, easy to remember FGF - FD combinations construed
from these models could reduce agent consumption
while not distracting the anesthesiologist from other
tasks during the induction period of anesthesia [3].
While kinetics of inhaled anesthetics in the anesthesia
circle system have already been modeled using mass bal-
ances [4-6], few of these models have been tested prospec-
tively [3,7]. We developed an empirical model for
desflurane administered in O2 with an ADU - AS/5
®
anesthesia machine (Anesthesia Delivery Unit, General
Electric, Helsinki, Finland) during the first 5 min of the
anesthetic, and prospectively tested whether it allows the
anesthesiologist to select a FGF - FD combination to attain
a FAt of the inhaled anesthetic within a specified time
interval (1 - 5 min) after turning on the vaporizer.
Methods
Part I. Model development
After obtaining IRB approval (OLV Hospital, Aalst,
Belgium) and written informed consent, 50 ASA physi-
cal status I or II patients presenting for plastic, urolo-
gic, or gynecologic surgery were enrolled. All patients
received oral alprazolam (0.5 or 1.0 mg) 1 h before the
scheduled start of surgery. After preoxygenation (8 L.
min-1 O2 FGF for 3 min), propofol (3 mg. kg
-1), rocur-
onium (0.7 mg. kg-1), and sufentanil (0.1 μg. kg-1) were
administered intravenously. After tracheal intubation,
ventilation was mechanically controlled by an ADU
anesthesia machine. Tidal volume and respiratory rate
were set fixed at 500 mL and 10 breaths. min-1,
respectively.
In a particular patient, one (fixed) O2 FGF and des-
flurane FD combination was used, with the FGF ranging
from 0.5 tot 5 L. min-1 and FD from 6 to 18%; this FGF
- FD combination was chosen randomly (random func-
tion in excel). Preliminary trials indicated what combi-
nations were likely to lead to a desflurane FA less than
1% after 2 min or less than 2% after 5 min, and these
were not considered.
Inspired and expired gases were analyzed by a multi-
gas analyzer (Datex-Ohmeda Compact Airway Module
M-CAiOV®, Datex-Ohmeda, Helsinki, Finland) and
downloaded into a spreadsheet every 10 seconds. Gases
were sampled at the distal end of the endotracheal tube
using a piece of sampling tubing placed through an
Arndt Multi-Port Airway Adapter® (Cook Medical Inc.,
Bloomington, IN). Gases sampled by the gas analyzer
were redirected to the anesthesia circuit via the expira-
tory limb. The study was terminated after 5 minutes, or
earlier when the end-expired desflurane concentration
had reached 8%. All values above 8% were eliminated
from further analysis. The 5 min period was somewhat
arbitrarily defined as the wash-in period because it
encompasses (1) anesthesia circuit wash-in; (2) FRC
wash-in; (3) early uptake by the VRG; (4) and the wan-
ing effects of propofol after about 5 min.
All measurements were done with the same anesthesia
machine and gas analyzer. The ADU® circle system
volume is 3.4 L. The fresh gas flow inlet is located distal to
the inspiratory valve. Fresh gas flow compensation is used
to compensate for the inspiratory fresh gas flow during
inspiration. The vaporizer output was measured at the
common gas outlet by the same gas analyzer and com-
pared with the dial setting using linear and non-linear
regression because (1) the vaporizer output may not
match the dial setting; (2) we wanted to be able to general-
ize the results to other ADU® units; and (3) we wanted to
exclude that certain performance error patterns could be
related to systematic vaporizer error. Based on 229 mea-
surements in 48 patients in this study, the actual desflur-
ane vaporizer output (%) could be described as -0.72 +
1.075*dial setting (r2 = 0.98); the vaporizer’s output tended
to increase with lower FGF (Figure 1).
A model was build to relate FA to FGF, FD, time, and the
following patient covariates: age, height, and weight. A
constant ventilation allowed us to at least standardize cir-
cuit and FRC wash-in; after 5 min, ventilation can easily
be adjusted to the desired end-expired CO2 concentration.
All values before 1 min were deleted because zero values
are hard to work with mathematically, and because the
Figure 1 Vaporizer performance error. Vaporizer performance
error (PE) with different fresh gas flows (FGF). PE (%) = 100*
(measured output - vaporizer dial)/vaporizer dialed. Thick line =
linear regression, with PE = 4.101-1.902*FGF (r2 = 0.23); grey line =
non-linear regression (third order polynomial), with PE = 6.990 -
5.959*FGF + 1.099*FGF2 - 0.05192*FGF3.
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model was only supposed to model the FGF - FD - time
relationship between 1 and 5 min. Initial model building
and parameter exploration were done in Excel using
Solver® (Microsoft, Seattle, WA). The initial choice of
mathematical functions was guided by three assumptions.
First, because FA rises exponentially, a one exponential
function was used to describe the rise of FA. Second, the
effect of a higher FD was modeled as curvilinear (assuming,
for example, that doubling FD would lead to a doubling of
FA). Third, the effect of FGF was modeled with a single
exponential (increasing as FGF is lowered). By trial and
error, these and additional functions were added, deleted,
modified, etc. to minimize the sum of least squares (differ-
ence between measured and predicted FA) using Solver
(Excel). Residuals were plotted against height, weight, and
age to search for covariate effects by visual inspection and
by linear regression. Finally, the model was tested for par-
simony using NONMEM’s Minimum Objective Function
(ICON Development Solutions, Dublin, Ireland).
Part II. Prospective testing
The model equation derived in part I was solved for FD
using Mathematica (Mathematica for Windows, Version
4.0, Wolfram Research Inc, Champaign, IL). The result-
ing equation predicts the FGF - FD combinations the
anesthesiologist can use to attain a FAt within the same
time interval used during model development (i.e.,
between 1 and 5 min) using a single FD and FGF setting,
and takes into account the covariate effects derived dur-
ing model building (see results section for actual
equation).
Management of the patients during prospective testing
only differed in the manner in which FGF and FD were
selected. Patients received desflurane in O2 with the
goal to reach a FAt of 3.5% after 3.5 min (n = 40), 5%
after 5 min (n = 37), or 6% after 4.5 min (n = 37). The
number of patients was chosen based on prior experi-
ence. After entering the time and FAt as well as signifi-
cant patient covariates in the equation, the equation
describes all possible FGF - FD combinations that reach
the FAt at the desired time for a patient with the parti-
cular characteristics entered into the equation. The fixed
FGF that was going to be used in the individual patient
was randomly selected (using Excel’s random function)
and entered in the equation, yielding the FD to be used.
Because the resolution of the desflurane vaporizer is
0.5%, the nearest value was chosen. FGF values requir-
ing an FD above the vaporizer limit (18%) obviously
could not be tested.
To allow us to compare model performance between
the three subgroups (3.5% after 3.5 min, 5% after 5 min,
or 6% after 4.5 min), the performance error (PE) for
each patient was calculated as 100*((FA measured - FA
predicted)/FA predicted), and the absolute performance
error (APE) as the absolute value of PE. Next, for each
subgroup, the following were examined: (1) bias and
accuracy, using the median performance error (MDPE,
median of all PE) and median absolute performance
error (MDAPE, median of all APE) [8]; (2) the relation-
ship between FGF and PE (and APE) using linear regres-
sion (linear correlation) and a third order polynomial
(non-linear effects) to help assess whether the model
systematically over- or underestimated the end-expired
desflurane concentration with increasing FGF.
Results
Part I. Model derivation
Patient demographics are presented in Table 1. The fol-
lowing equation described measured FA best:
FA = (1/(Ht ∗ 0.1) ∗ (2.55 ∗ FGF + 1348 ∗ (1 − e(−FGF∗−0.23)
+2.49 ∗ (1 − e(−FGF∗0.24)) ∗ 0.39 ∗ FD) ∗ (0.03 ∗ (1 − e(Time/−4.08)))),
with Ht = height (cm), Time = time after turning on
the vaporizer (min), and with FA, FD and FGF expressed
in %, %, and L. min-1, respectively. The measured versus
model predicted FA are presented in Figure 2. Only
height decreased the NONMEM minimum objective
function significantly, and therefore is the only patient
covariate to be incorporated into the model. Plots of the
residuals versus patient covariates are presented in
Figure 3. Note that the rebreathing function (1-e(-FGF*-
0.23)+2.49*(1-e(-FGF*0.24))*0.39*FD), will cause the FA to
decrease again at high flows, an effect caused by a
decreased vaporizer output with high FGF due to
cooling.
Part II. Prospective testing
Solving the above derived equation for FD yields the fol-
lowing equation:
FD = −(e(−FGF∗−0.23+FGF∗0.24) ∗ (e(FGF∗−0.23) ∗ FAt ∗ Ht ∗ 0.1 − e(FGF∗−0.23)
∗FGF ∗ 2.55 + 40.46 − e(FGF∗−0.23) ∗ 40.46 + e(FGF∗−0.23+Time/−4.08) ∗ 40.46
−e(Time/−4.08) ∗ 40.46))/((−1 + e(FGF∗0.24)) ∗ (−1 + e(Time/−4.08)) ∗ 39.29)
where Time = desired time lag after turning on the
vaporizer to reach FAt (any value between 1 and 5 min);
and Ht = patient height in cm. After entering FAt, Time,
Ht, and chosen FGF, the corresponding FD to reach FAt
within the desired time lag can be calculated. Because
any FGF can be chosen, this will result in a virtually
infinite number of FGF - FD combinations. Patient
demographics for each subgroup are presented in Table
1. Performance parameters PE, MDPE, APE and
MDAPE for the three subgroups are presented in Figure
4, that also includes the linear regression line and a
third order polynomial fit to examine whether PE and
APE systematically increased or decreased with increas-
ing FGF. MDPE and MDAPE were -2.9 and 7.0% in the
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3.5% after 3.5 min group, -3.4 and 11.4% in the 5% after
5 min group, and -16.2 and 16.2% in the 6% after 4.5
min groups, respectively. There was a very weak (linear)
correlation between FA and age, but not with height
(effect incorporate in model) and weight (Figure 5).
Discussion
An empirical equation can be derived that predicts FGF
- FD combinations that attain a FAt of an inhaled anes-
thetic after a predefined time lag. With modern comput-
ing power such an equation can easily be entered into
an Excel file to calculate the required FD for any chosen
FGF. While our current model will need to be refined
and tested for different patient populations, agents, car-
rier gases, and anesthesia machines, our results prove
the concept.
The concept of using an equation to predict the
required FD for any chosen FGF to help the anesthesiolo-
gist attain and maintain a FAt is not new. Three decades
ago, Lowe described a “general anesthetic equation” that
describes the FGF - FD relationship in a circle breathing
system [4]. That equation was derived by considering
Table 1 Patient demographics, presented as mean (standard deviation)
Group Number Age (years) Weight (kg) Height (cm)
Model derivation group 50 52 (15) 70 (14) 166 (9)
3.5% after 3.5 min group 40 46 (16) 72 (12) 170 (9)
5% after 5 min group 37 53 (18) 77 (16) 170 (8)
6% after 4.5 min group 37 52 (16) 73 (14) 169 (9)
Figure 2 Model derivation: measured versus model predicted
end-expired desflurane concentrations (FA, %). Thick line =
identity line; lines above and below are + or - 20% deviation from
identity line.
Figure 3 Model derivation: final plot of residual error (modeled
minus measured FA) versus patient covariates. A = age, B =
height, and C = weight. There was no (linear) correlation with age
(r2 = 0.00), height (r2 = 0.01 after implementing it as a covariate in
the model) and weight (r2 = 0.00).
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mass balances in the circle system and by making certain
assumptions regarding the uptake pattern of the agent
(the square root of time model) [4]. The model was
mainly developed to facilitate the use of closed circuit
anesthesia, and has never been tested prospectively
across the entire FGF spectrum. Our current empirical
model only describes the first 5 min of inhaled agent
administration, the wash-in phase, and is to be combined
(in the future) with a model that predicts the FGF - FD
relationship during the maintenance phase.
The MDPE (-2.9, -3.4, and -16.2%) as well as the
MAPDE (7.0, 11.4, and 16.2%) are within the limits
deemed acceptable for target controlled infusion systems
for intravenous anesthetic agents (MDPE <10-20% and
MDAPE 20 - 40%) [9]. Still, there is some degree of mis-
specification of the model that could not be accounted for:
there are some outliers of 30%, and the error seems larger
in the lower FGF range. The latter could be explained by
the fact that uptake differs almost 170% among patients
[10,11]. This variability in uptake may have a more pro-
nounced effect on FA with lower FGF because increased
rebreathing causes the effect of the (unpredictable)
amount of uptake on the composition of the inspired mix-
ture to become more pronounced. During modeling,
attempts are made to improve the degree of misspecifica-
tion by taking the effect of covariates into account. How-
ever, only height significantly decreased the minimum
objective function. Weight (within the range encountered
in the study population) has previously been shown not to
correlate with agent uptake [10-13]. Therefore, it is no sur-
prise that weight did not improve the minimum objective
function during model development, and that there was
no significant effect of weight as a covariate. Nevertheless,
future modeling in a still larger patient group might reveal
Figure 4 Model performance. Performance Error (PE, %, closed circles, group 3.5% after 3.5 min = A; group 5% after 5 min = C, and group 6%
after 4 min = E) and Absolute Performance Error (APE, %, open circles, group 3.5% after 3.5 min = B, group 5% after 5 min = D, and group 6%
after 4 min = F), with their respective linear regression line (hatched), polynomial fit (grey line), and median performance error (MDPE,
continuous black line, A, C, and E) and median absolute performance error (MDAPE, continuous black line, B, D, and F).
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for example that lean body weight might be a useful cov-
ariate. Age did not improve NONMEMs minimum objec-
tive function during model development either, but visual
inspection of the FA versus age plot during prospective
testing suggests FA to be higher with older age (r
2 ranged
from 0.04 - 0.18). Age might therefore still turn out to be
a useful covariate in a new model based on a larger num-
ber of patients. Other factors may be important - it may
be that model misspecification increases with altered phy-
siology and pathophysiology, e.g. when older, sicker
patients are included (patients in this study were relatively
healthy - ASA 1-2), when cardiac output is altered, or
when synergistic effects are likely to come into play (e.g.
with premedication).
Other limitations exist. The wash-in model may not
be applicable when spontaneous ventilation is allowed
immediately following intravenous induction of anesthe-
sia, because the irregular and inconsistent breathing at
that time does not allow the acquisition of reliable end-
expired concentrations. This also is an issue for modern
anesthesia machines that use automated closed-loop
end-tidal feedback administration of inhaled agents.
Also, the model is limited to a maximum end-expired
concentration of 8% - higher concentrations might be
needed in some patients, but this comes at a risk of irri-
tating the airway.
An empirical equation that describes the FGF - FD rela-
tionship may have some interesting applications. It can
be used to predict and depict the course of FA in the indi-
vidual patient over a wide range of FGF - FD settings dur-
ing the first 5 min of an anesthetic. In figure 6A, the
equation has been solved for a 176 cm tall patient to
describe the FA resulting from different FGF - FD combi-
nations after 1, 2, 3, 4, and 5 min (multi-colored graphs,
bottom to top, respectively; more detail on how this
graph was derived can be found in the Appendix). The
equation can further be used to calculate the FGF - FD
combinations that attain a FAt after a predefined time
interval. If the FAt would be 4.5% (the light blue surface),
the required FGF - FD combinations that attain 4.5%
Figure 5 Prospective testing. Linear regression between covariates (age, height, and weight) and residual error (predicted minus measured
end expired desflurane concentration) in the 3.5% after 3.5 min group (A, B, and C), the 5% after 5 min group (D, E, and F), and the 6% after 4.5
min group (G, H, and I).
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after 1, 2, 3, 4, and 5 min can be found by calculating the
intersection between the multicolored surfaces and the
light blue surface. These intersections are presented in
Figure 6B. This figure also illustrates how the equation
can be used to calculate the lowest FGF that could be
used with the maximum 18% vaporizer setting to attain a
certain FAt (i.e., it illustrates the FGF below which vapori-
zer output becomes inadequate to attain the FAt within
the specified time interval).
Conclusion
An empirical model is described that allows the deriva-
tion of a formula for each type of anesthesia machine
that predicts the FGF - FD combinations in a circle
breathing system that attain a target end-expired agent
concentration in a particular patient within a specified
time interval (1 - 5 min) after turning on the vaporizer.
The sequences are easily calculated in an Excel file and
simple to use (one fixed FGF - FD setting), and have the
potential to minimize agent consumption and reduce
pollution by allowing to determine the lowest possible
FGF that can be used.
Appendix: Derivation of Figure 6
According to the model, FA = (1/(Ht*0.1))*(2.55*FGF
+1348*(1-e(-FGF*-0.23)+2.49*(1-e(-FGF*0.24))*0.39*FD)*(0.03*
(1-e(Time/-4.08)))) with Ht = height (cm), Time = time after
turning on the vaporizer (min), and with FA, FD and FGF
expressed in %, %, and L. min-1, respectively.
Let us examine how the desflurane FA would evolve
for a 176 cm tall patient over the entire FGF-FD range
studied during model development. The surface describ-
ing desflurane FA after 3 min is calculated by entering
the following parameters into the above formula: Ht =
176; Time = 3; and a sufficient number of FGF - FD
combinations to allow the reconstruction of a surface in
Sigmaplot (Systat Software Inc, San Jose, CA, USA). The
multicolored surface in Figure 7 represents these pre-
dicted FA values after 3 min.
To determine which FGF - FD combinations result in
a FAt of e.g. 4.5% after 3 min, the intersection has to be
calculated between this target (the horizontal light blue
surface) and the multicolored surface that describes the
FA values with the entire FGF-FD range after 3 min
(Figure 7). This line can be calculated by entering Ht =
176, Time = 3, and FAt = 4.5 in the formula FD=-(e
(-FGF*-0.23+FGF*0.24)*(e(FGF*-0.23)*FAt*Ht*0.1-e
(FGF*-0.23)
*FGF*2.55+40.46-e(FGF*-0.23)*40.46+e(FGF*-0.23+Time/-4.08)
*40.46-e(Time/-4.08)*40.46))/((-1+e(FGF*0.24))*(-1+e(Time/-
4.08))*39.29). This intersection line is shown in Figure 8
and presents the virtually infinite number of FGF - FD
combinations that result in an FA of 4.5% after 3 min in
a 176 cm tall patient. It also illustrates that it is not pos-
sible to achieve this target with a FGF lower than 0.7 L.
min-1 because FD would have to be higher than the
maximum 18%. Note that the curve increases at high
FGF because vaporizer output decreases due to exces-
sive cooling.
Similar graphs can be developed for different time
intervals (between 1 and 5 min). The multicolored sur-
face in Figure 7 describes the desflurane FA after using a
range of FGF - FD combinations for 5 min; the
Figure 6 Visual presentation of model-based desflurane FA course in a fictive 176 cm tall patient. The multi-colored graphs (A) describe
the predicted FA resulting from different FGF - FD combinations after 1, 2, 3, 4, and 5 min (bottom to top, respectively). The intersection of these
surfaces with the FAt surface, in this example 4.5% desflurane (light blue horizontal surface), yields the corresponding FGF - FD combinations that
attain that FAt (B). The asterixes (*) indicate the lowest possible FGF that can be used to attain 4.5% desflurane at 1, 2, 3, 4, and 5 min because of
the maximum 18% vaporizer setting. More details are provided in the Appendix.
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intersection between this surface and the target 4.5%
surface (horizontal light blue surface) thus describes the
virtually infinite number of FGF - FD combinations that
result in an FA of 4.5% after 5 min in a 176 cm tall
patient (Figure 8). Figure 6 is a composite of these
graphs for the time intervals of 1, 2, 3, 4, and 5 min
with a FAt of 4.5%.
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Figure 7 Multicolored surface describing desflurane FA after 3 min for a 176 cm tall patient over the FGF - FD range studied. The FGF -
FD combinations that result in a FAt of 4.5% (light blue horizontal surface) after 3 min are found by calculating the intersection between this
target (the light blue surface) and the multicolored surface; these FGF - FD combinations are presented in B. The asterix (*) indicates the lowest
possible FGF that can be used to attain 4.5% desflurane at 3 min because of the maximum 18% vaporizer setting.
Figure 8 Multicolored surface describing desflurane FA after 5 min for a 176 cm tall patient over the FGF - FD range studied. The FGF -
FD combinations that result in a FAt of 4.5% (light blue surface) after 5 min are found by calculating the intersection between this target (the
light blue surface) and the multicolored surface; these FGF - FD combinations are presented in B. The asterix (*) indicates the lowest possible FGF
that can be used to attain 4.5% desflurane at 5 min because of the maximum 18% vaporizer setting.
Hendrickx et al. BMC Anesthesiology 2011, 11:13
http://www.biomedcentral.com/1471-2253/11/13
Page 8 of 9
Authors’ contributions
JH, HL and ADW conceptualized the idea, designed the study, and
performed mathematical analysis. All authors participated in data analysis
and interpretation and drafting of the manuscript. All authors read and
approved the final manuscript.
Competing interests
Jan Hendrickx has received speaker fees and reimbursement of travel
expenses related to presentation of his work from GE, Abbott, and Baxter.
Received: 7 December 2010 Accepted: 24 June 2011
Published: 24 June 2011
References
1. Hendrickx JFA, Vandeput DM, De Geyndt AM, De Ridder KP, Haenen JS,
Deloof T, De Wolf AM: Maintaining sevoflurane anesthesia during low-
flow anesthesia using a single vaporizer setting change after
overpressure induction. J Clin Anesth 2000, 12:303-7.
2. De Cooman S, De Mey N, Dewulf BB, Carette R, Deloof T, Sosnowski M, De
Wolf AM, Hendrickx JF: Desflurane consumption during automated
closed-circuit delivery is higher than when a conventional anesthesia
machine is used with a simple vaporizer-O2-N2O fresh gas flow
sequence. BMC Anesthesiol 2008, 8:4.
3. Lerou JG, Verheijen R, Booij LH: Model-based administration of inhalation
anaesthesia. 4. Applying the system model. Br J Anaesth 2002, 88:175-83.
4. Lowe HJ, Ernst EA: The quantitative practice of anesthesia - use of closed
circuit. Baltimore, Williams & Wilkins; 1981.
5. Lerou JG, Dirksen R: A system model for closed-circuit inhalation
anesthesia. I. Computer study. Anesthesiology 1991, 75:345-55.
6. Mapleson WW: The theoretical ideal fresh-gas flow sequence at the start
of low-flow anaesthesia. Anaesthesia 1998, 53:264-72.
7. Ip-Yam PC, Goh MH, Chan YH, Kong CF: Clinical evaluation of the
Mapleson theoretical ideal fresh gas flow sequence at the start of low-
flow anaesthesia with isoflurane, sevoflurane and desflurane. Anaesthesia
2001, 56:160-4.
8. Varvel JR, Donoho DL, Shafer SL: Measuring the predictive performance of
computer-controlled infusion pumps. J Pharmacokinet Biopharm 1992,
20:63-94.
9. Swinhoe CF, Peacock JE, Glen JB, Reilly CS: Evaluation of the predictive
performance of a ‘Diprifusor’ TCI system. Anaesthesia 1998, 53:61-7.
10. Westenskow DR, Jordan WS, Hayes JK: Uptake of enflurane: a study of the
variability between patients. Br J Anaesth 1983, 55:595-601.
11. Lockwood GG, Chakrabarti MK, Whitwam JG: The uptake of isoflurane
during anaesthesia. Anaesthesia 1993, 48:748-52.
12. Hendrickx JF, Soetens M, Van der Donck A, Meeuwis H, Smolders F, De
Wolf AM: Uptake of desflurane and isoflurane during closed-circuit
anesthesia with spontaneous and controlled mechanical ventilation.
Anesth Analg 1997, 84:413-8.
13. Hendrickx JFA, Van Zundert AAJ, De Wolf AM: Sevoflurane
pharmacokinetics: effect of cardiac output. Br J Anaesth 1998, 81:495-501.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2253/11/13/prepub
doi:10.1186/1471-2253-11-13
Cite this article as: Hendrickx et al.: Mathematical method to build an
empirical model for inhaled anesthetic agent wash-in. BMC
Anesthesiology 2011 11:13. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hendrickx et al. BMC Anesthesiology 2011, 11:13
http://www.biomedcentral.com/1471-2253/11/13
Page 9 of 9
